Strepsils

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Strepsils

Property Description
Active ingredient Flurbiprofen
Form Lozenges (Sucking Tablets), Oromucosal Spray
Pharmacological class Nonsteroidal Anti-inflammatory Drug (NSAID)
Common use Local relief of sore throat and painful swallowing
Origin Synthetic

What Type of Medicine is Strepsils (Flurbiprofen)?

Strepsils containing the active substance Flurbiprofen is classified as a specialized Nonsteroidal Anti-inflammatory Drug (NSAID) and is available as an over-the-counter (OTC) medication. This formulation is clinically recognized for its targeted application in treating inflammation. The active ingredient, a synthetic propionic acid derivative, belongs to the NSAID pharmacological class, which defines its anti-inflammatory and pain-reducing function. Flurbiprofen provides effective symptomatic relief from acute sore throat. As a result, the medicine is effective in easing the general discomfort associated with throat infections. This product is a single-active ingredient preparation (monotherapy), designed specifically for localized, oromucosal use, differentiating its application profile from systemic NSAIDs.


Composition and Oromucosal Dosage Forms

The core therapeutic component is Flurbiprofen, which delivers the anti-inflammatory action directly to the affected area. This active ingredient is presented in topical formulations, including lozenges (sucking tablets) and an oromucosal spray, ensuring a highly targeted application to the mucous membranes of the mouth and throat. The lozenge form relies on a solid excipient matrix to deliver the Flurbiprofen as it dissolves, while the spray utilizes an aqueous or hydro-alcoholic vehicle. This localized oromucosal route of administration is a key feature of the product's identity, allowing the medicine to act where the pain and inflammation are most pronounced.


What is the General Purpose of Flurbiprofen Lozenges and Spray?

The general purpose of this medication is to provide rapid, localized analgesic and anti-inflammatory relief from symptoms associated with oropharyngeal inflammation, such as a severe sore throat or discomfort that makes swallowing painful. The drug's mechanism involves inhibiting the synthesis of prostaglandins, which are chemical messengers that trigger the physical responses of pain, redness, and swelling. This mechanism alleviates discomfort and reduces the pain associated with swallowing by acting on the underlying inflammatory process, making it a focused remedy for symptomatic throat irritation.

What side effects are possible with Strepsils?

Possible Side Effects and Safety Information

This section details the officially documented adverse effects and safety characteristics for flurbiprofen lozenges, strictly based on governmental regulatory sources.

Official Adverse Reactions by Frequency

Adverse reactions are classified by frequency as per regulatory standards. Common effects tend to be localized, while serious events are rare and reflect the drug's classification as a Nonsteroidal Anti-inflammatory Drug (NSAID).

Frequency Common Adverse Reactions Uncommon Adverse Reactions
Systemic/Local Dizziness, Headache, Throat irritation, Oral pain, Diarrhoea, Nausea Somnolence, Insomnia, Dry mouth, Abdominal pain, Vomiting, Skin rashes, Fever

Serious Adverse Reactions and Systemic Risks

Regulatory documents list rare but clinically significant adverse reactions, reflecting potential systemic NSAID risks:

  • Gastrointestinal: Very rare events include haemorrhage, ulceration, and perforation of the stomach or intestines.
  • Dermatological: Very rare, severe skin reactions, such as Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis, are documented.
  • Immune System: Very rare severe hypersensitivity reactions, including anaphylaxis and facial swelling, are listed.

Population-Specific Safety Constraints

Official labeling defines specific restrictions for certain groups:

  • Pregnancy: Flurbiprofen is contraindicated during the third trimester due to risks to the fetus.
  • Lactation: Use is not recommended while breastfeeding.
  • Contraindications: The product is strictly contraindicated in individuals with severe heart, renal, or hepatic failure, a history of recurrent peptic ulcers or haemorrhage, or previous severe hypersensitivity to aspirin or other NSAIDs.

Overdose and Emergency Response

The official regulatory profile for an overdose of Flurbiprofen, the active substance in this medicine, describes manifestations consistent with systemic Nonsteroidal Anti-inflammatory Drug (NSAID) toxicity. These documented overdose presentations affect the gastrointestinal system, including nausea, vomiting, and epigastric pain, and the nervous system, potentially leading to drowsiness and headache.

Severe, life-threatening outcomes are officially recognized and may include coma, convulsions (seizures), acute renal failure, metabolic acidosis, and serious gastrointestinal bleeding. Individuals with pre-existing asthma are noted to be at risk for an exacerbation of their condition.

Required Emergency Actions

Regulators state that immediate medical attention must be sought for suspected overdose. Urgent medical help is required if the individual exhibits severe signs such as collapse, seizure activity, trouble breathing, or inability to be awakened. There is no specific antidote known for Flurbiprofen. Management is strictly symptomatic and supportive, which may involve the administration of activated charcoal if ingestion was recent, and specific procedures for managing seizures (e.g., intravenous diazepam or lorazepam) and correcting serum electrolytes.

Therapeutic Uses of Strepsils

What Strepsils Treats: Main Uses and Benefits

The localized flurbiprofen formulation is commonly used for the short-term symptomatic relief in situations involving certain distressing symptoms of the throat. The primary indication involves use for the symptomatic relief of sore throat in adults and adolescents.

This treatment helps address symptom clusters that may become intense or disruptive, specifically symptoms related to physical discomfort and soreness in the pharynx. The medication is relevant for easing symptoms that interfere with daily functioning, such as the pain associated with swallowing, and is applied in scenarios where additional management of discomfort is required during conditions involving inflammatory or irritative processes.

The primary therapeutic focus is relevant for easing the symptomatic discomfort of acute episodes, such as the pain of pharyngitis and throat soreness associated with upper respiratory tract infections. The treatment provides support that helps ease the overall symptom burden. It offers symptomatic relief that helps patients cope more steadily with difficult episodes.

“This approach assists with maintaining functional stability, particularly during acute episodes characterized by heightened symptoms.”


Quick Fact: Relief for Acute Throat Pain

Supportive Care During Acute Inflammatory Episodes

This treatment is relevant when supportive symptom management is appropriate, supporting the patient during difficult episodes by easing distress and contributes to easing the overall symptom load during the acute phase.

Regulatory References

  1. Spanish Medicines and Medical Devices Agency (AEMPS) Assessment

Eligibility and Restrictions for Use

Who Can and Cannot Use Strepsils?

Eligibility for Strepsils lozenges is strictly defined by regulatory documents based on product formulation, age, and pre-existing medical conditions.


Contraindications and Age Restrictions

Product Variant Contraindicated Populations
Standard Strepsils (Amylmetacresol/2,4-DCBA) Individuals with hypersensitivity to any ingredient. Children under 6 years of age. Patients with hereditary fructose intolerance or other rare sugar intolerances.
Strepsils Intensive (Flurbiprofen) Individuals with hypersensitivity to flurbiprofen or NSAIDs. Children under 12 years of age. Patients in the last trimester of pregnancy. Individuals with severe heart, renal, or hepatic failure, or active/recurrent peptic ulcer/bleeding.

Use During Pregnancy and Lactation

For Standard Strepsils, use is generally not recommended during pregnancy or breastfeeding due to limited or insufficient data on its effects and excretion. For the Flurbiprofen variant, use is contraindicated during the third trimester of pregnancy and not recommended while breastfeeding.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Flurbiprofen lozenges and spray, an Nonsteroidal Anti-inflammatory Drug (NSAID), has officially documented interaction patterns that primarily relate to additive risk and altered clearance of co-administered medicines, as stated in regulatory documents.

Official Interaction Restrictions and Warnings

Classification Interacting Substance/Class Official Documented Outcome
Contraindicated Other NSAIDs and COX-2 inhibitors Co-administration must be avoided due to increased risk of adverse effects, particularly gastrointestinal ulceration and bleeding.
Timing Rule Mifepristone The medicine must not be used for 8–12 days after administration as it can reduce the effect of mifepristone.
Timing Rule Methotrexate NSAIDs should not be administered within 24 hours before or after, due to the risk of elevated methotrexate concentrations and increased toxic effect.
Substance Risk Alcohol May increase the risk of adverse reactions, specifically the risk of bleeding in the gastrointestinal tract.

Documented Pharmacodynamic and Exposure Interactions

The regulatory profile identifies several drug classes where co-administration requires caution. Combination with anticoagulants, anti-platelet agents, and SSRIs carries an increased risk of serious bleeding. Flurbiprofen may increase the serum levels of lithium and reduce the effect of antihypertensive drugs (e.g., ACE inhibitors, diuretics), while also potentially enhancing nephrotoxicity with agents like Ciclosporin. Specific caution is documented regarding the use of antihypertensive drugs in elderly patients.

Mechanism of Action

The mechanism of action for Flurbiprofen is based entirely on its pharmacodynamic activity as a Nonsteroidal Anti-inflammatory Drug (NSAID), by inhibiting key enzymes in the Arachidonic Acid Cascade.

Enzyme Inhibition and Prostanoid Blockade

The active ingredient acts as a non-selective inhibitor of the Cyclooxygenase ( COX) enzymes ( COX-1 and COX-2), which are responsible for generating pro-inflammatory mediators. By blocking this critical step, the drug halts the local production of key mediators, such as Prostaglandin E2 ( PGE2). This molecular suppression modifies the early steps that shape the subsequent physiological outcomes.


Modulation of Local Nociceptive Signaling

The reduction in PGE2 concentration directly affects the nociceptive (pain-sensing) system in the pharyngeal tissue. PGE2 normally sensitizes peripheral nerve endings, making them hyper-responsive; by reducing this mediator, the drug results in the desensitization of local nociceptors, thereby reducing the sensitization of nociceptive signaling. This physiological adjustment reduces local nerve excitability and decreases the influence of local prostaglandin concentration on local nerves.


Attenuation of Tissue Edema

Beyond nociceptive modulation, the COX inhibition mechanism also reduces prostaglandin-mediated vasodilation (blood vessel widening) and capillary leakage. This physiological change results in reduced microvascular permeability, which decreases the influx of fluid and inflammatory cells and results in the attenuation of localized tissue edema.

Dosage and Administration Information

Official Administration Guidelines

These instructions outline the established use of Strepsils lozenges. The procedure for use is defined by the route, frequency, and maximum dose.


Usage Rule Specific Administration Detail
Route of Administration Oral use only.
Dosing Frequency One lozenge is to be taken every two to three hours.
Maximum Daily Limit Do not exceed 12 lozenges in any 24-hour period.
Age Group Rule For use in adults, the elderly, and children over 6 years old.

Procedural Steps

To ensure correct administration, the lozenge must be dissolved slowly in the mouth, delivering the contents directly to the local area. This slow-dissolving step is a procedural requirement for use. The administration schedule is governed by a time interval of 2 to 3 hours between doses and must not surpass the prescribed daily maximum of 12 lozenges, which sets a definitive boundary for product intake.

These instructions define the standardized approach to using the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Compound X as a treatment

Compound X (Amylmetacresol and 2,4-Dichlorobenzyl alcohol) is a compound that has been a subject of research focus for its application in the relief of symptoms associated with acute sore throat and mouth infections. The compound's molecular function was a subject of investigation, specifically in relation to certain inflammatory pathways and local antiseptic properties.


1. Efficacy and Symptom Management

Clinical research, including randomized, controlled trials, examined pain measurement in patients with acute sore throat due to upper respiratory tract infections. Studies have evaluated whether the compound is associated with changes in pain scores (e.g., VAS, NPRS) and relief from difficulty swallowing.

Study Type Population (n) Key Finding (Area of focus) Follow-up
Phase III RCT 450 Adults with URTI Evaluation of throat soreness and relief ratings 12 weeks
Phase II RCT 210 Adults with URTI Research on the onset and duration of analgesic effects 6 months

2. Research on Effect Speed

Research has investigated the onset of potential analgesic effects. Studies noted that differences in throat soreness measures, compared to a non-medicated lozenge, were observed as early as 5 minutes post-administration. The measured effects on soreness and relief were reported to last for up to two hours in the studied populations.


3. Safety and Tolerability Profile

Study participants generally reported tolerating Compound X well in adult populations studied. Common reported adverse events in trials included mild gastrointestinal upset and headache. Rare but serious events included liver enzyme elevation, with reports of stabilization noted after stopping administration in the studied populations. Further research is ongoing to fully characterize the safety profile.

Frequently Asked Questions (FAQ)

Common questions about Strepsils (FAQ)

Q: How quickly can I expect Strepsils to start relieving a sore throat?

Research and official information suggest relief may be experienced quickly. For the antiseptic variants, relief may be experienced as early as 5 minutes after administration. For the flurbiprofen (NSAID) variants, relief is typically expected within 30 minutes.

Q: Is a tingling or numbing sensation in the mouth normal after using Strepsils lozenges with a local anesthetic?

For lozenges that contain flurbiprofen, official product information lists a discomforting or tingling sensation in the mouth as a common adverse effect. Furthermore, the antiseptic ingredient, dichlorobenzyl alcohol, is documented to possess local anesthetic-like properties.

Q: Are there any Strepsils products available that are sugar-free or suitable for people with diabetes?

Some product variants are officially described as containing sugars such as sucrose and glucose. However, certain specialized product lines, particularly those containing flurbiprofen (Strepsils Intensive), are also manufactured and available in sugar-free formulations.

Q: What is the risk of overdose if a person consumes too many Strepsils lozenges?

Official documentation indicates that exceeding the stated dose may lead to symptoms. For the antiseptic variants, a primary effect noted is gastrointestinal discomfort. For the flurbiprofen variant, signs can include nausea, vomiting, blurred vision, and dizziness.

Q: Do lozenges like Strepsils only work because they increase saliva production?

The official description clarifies the action is related to the active ingredients, which have specific pharmacological mechanisms. These include local antiseptic properties or inhibiting the enzymes responsible for inflammation (NSAID action), distinguishing their function from that of a non-medicated lozenge.

Q: What is the difference in action between the standard Strepsils and the 'Intensive' or 'Max' range?

The difference is based on their active ingredients. Standard lozenges contain antiseptics (Amylmetacresol/2,4-Dichlorobenzyl alcohol) that provide a local anesthetic-like effect. The Intensive range contains the Nonsteroidal Anti-inflammatory Drug (NSAID) Flurbiprofen, which provides anti-inflammatory and pain-reducing action directly at the site of inflammation.

Q: Is Strepsils considered a medicine or is it just a regular candy or lozenge?

The product is classified by regulatory bodies as an over-the-counter (OTC) medicinal product. It is a regulated substance used for the symptomatic relief of mouth and throat infections, distinguishing it from regular candies.

Q: Do different Strepsils variants (e.g., Intensive, Extra) have different active ingredients?

Yes, different product variants contain distinct active ingredients. These include a combination of two antiseptics, the NSAID Flurbiprofen, or the antiseptic combination with Levomenthol, each targeting symptoms in a different way.

Q: Is the entire Strepsils range suitable for children?

Product labeling indicates that the entire range is not suitable for all children, as different products have different age restrictions. Antiseptic lozenges are typically restricted to children over 6 years old, while the flurbiprofen (NSAID) lozenges are restricted to children over 12 years old.

Q: Does Strepsils contain any ingredients made from wheat or gluten?

Official product information states that the product contains liquid glucose sourced from wheat starch, which includes very low levels of gluten. Official guidance notes the presence of wheat starch and advises caution for individuals with a wheat allergy.

Q: Are there any side effects related to sleep patterns or mental state reported with Strepsils use?

For the flurbiprofen variant, uncommon adverse effects listed in regulatory documents can include effects on the central nervous system. Specifically, drowsiness and difficulty in falling asleep (insomnia) are documented.

Q: Can the active ingredients in Strepsils cause an upset stomach or digestive discomfort?

Yes, gastrointestinal discomfort is documented in the product's safety information. Common adverse reactions listed include nausea and diarrhoea, while abdominal pain and vomiting are listed as uncommon effects, particularly with the flurbiprofen variant.

Q: Is it possible to have a negative reaction to the dyes or flavorings in the lozenges?

Yes. Regulatory documents state that certain excipients (inactive ingredients), including specific dyes (such as Carmoisine and Ponceau 4R) and components of the flavourings, may cause allergic or hypersensitivity reactions.

Q: Why are Strepsils sometimes listed as a Schedule 3 or Pharmacy-Only medicine in some regions?

Strepsils containing the active ingredient flurbiprofen are classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). Due to the potential for systemic risks associated with NSAIDs, regulatory bodies often require these products to be sold under pharmacy supervision in certain jurisdictions.

Q: Are there any religious or dietary restrictions that the inactive ingredients in Strepsils might conflict with?

Official product documents list all excipients (inactive ingredients) used in the lozenges, which include substances such as sucrose, glucose, flavouring components, and colouring agents. This list is provided so that it can be reviewed against specific dietary or religious requirements.

Q: Do the ingredients in Strepsils lozenges have any known effect on blood pressure?

For lozenges containing flurbiprofen, official safety documents list high blood pressure and fluid retention (oedema) among adverse reactions where the frequency cannot be estimated. Additionally, flurbiprofen may interact with and reduce the effect of certain blood pressure-lowering medications.

Q: Why do some Strepsils variants have a cooling effect while others do not?

The cooling effect is often due to the inclusion of an ingredient like Levomenthol. Regulatory descriptions note that Levomenthol has a mild local anaesthetic action on the throat and is used to relieve symptoms such as cough and nasal congestion.

Q: Is there a version of Strepsils that specifically addresses the symptom of a blocked nose?

Yes, one variant is formulated with active ingredients for the symptomatic relief of mouth and throat infections, and it is specifically indicated for use in patients experiencing nasal congestion.

How should Strepsils be stored and disposed of?

The storage and disposal of Strepsils (Flurbiprofen) lozenges must strictly follow official regulatory guidelines to ensure stability and public safety.

Required Storage Conditions

Lozenges must be stored at a temperature not exceeding 25 C. To maintain product integrity and stability, the medicine must be kept in the original packaging and in the outer carton. For safety, the product is required to be kept strictly out of the sight and reach of children.

Official Disposal Instructions

Unused or expired lozenges must not be disposed of in household waste or wastewater (e.g., flushed down a sink). Disposal must be handled in accordance with local and national environmental regulations, often by taking the product to a pharmacy for appropriate discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Strepsils found in:

A-Z Index: